No Data
No Data
Junshi Bio (01877) has cumulatively repurchased 0.8159 million shares.
Junshi Bio (01877) announced that as of July 31, 2024, the company has successfully gone through the Shanghai Stock Exchange's trading...
Junshi Biosciences (688180.SH): Has repurchased 0.0828% of the shares.
Junshi Bio (688180.SH) announced on July 31st that as of July 31st, 2024, the company has cumulatively repurchased 815,871 shares of its stock through the Shanghai Stock Exchange trading system in a centralized bidding trading method, representing 0.0828% of the total share capital of the company. The highest and lowest repurchase transaction prices were RMB 41.69/share and RMB 29.03/share, respectively, and the total amount paid, excluding transaction fees such as stamp duty and brokerage commissions, was RMB 30,883,207.73.
Junshi Biosciences Gets Europe's Positive Opinion on Toripalimab
Junshi Bio: Teriprizumab received positive opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency.
Junshi Bio (01877) announced that the market approval application for Tripletuzumab (European commodity name: LOQTORZI) has received positive opinions from the EMA Committee for Medicinal Products for Human Use, suggesting its approval for the treatment of two indications: Tripletuzumab combined with cisplatin and gemcitabine for first-line treatment of recurrent, unresectable or metastatic nasopharyngeal carcinoma in adults who are not eligible for surgery or radiotherapy, and Tripletuzumab combined with cisplatin and paclitaxel for first-line treatment of unresectable advanced/recurrent or metastatic esophageal squamous cell carcinoma in adults. The European Commission will take into account the positive opinions of the CHMP for further consideration.
China Securities Co., Ltd. expects that the "expanding domestic demand" trade will gradually grow, covering cyclical and growth stocks.
China Securities Co.,Ltd. released a research report stating that it is expected that the 'expanding domestic demand' trade will gradually grow, covering both cyclical and growth stocks.
Junshi Bio (688180.SH): The trupli monoclonal antibody has received a positive opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency.
On July 28th, Gelunhui reported that Junshi Bio (688180.SH) announced that the application for marketing authorization of its product toripalimab (European commodity name: LOQTORZI) has received positive opinions from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), which recommends its approval for the treatment of two indications: toripalimab combined with cisplatin and gemcitabine for the first-line treatment of adult patients with recurrent, unresectable or metastatic nasopharyngeal carcinoma who are not suitable for radiotherapy, and toripalimab combined with cisplatin and paclitaxel for the treatment of unresectable advanced / recurrent or metastatic esophageal squamous cell carcinoma in adults.
No Data